Medicus Pharma, a small precision-oncology biotech headquartered in Conshohocken, Pennsylvania, has licensed an antibody-drug conjugate that Pfizer inherited through its $43 billion Seagen acquisition and then shelved earlier this year. Under the co-development and licensing agreement signed September 2, Medicus is paying Pfizer $12 million upfront for rights to the compound, with Pfizer eligible to collect more than $1 billion in milestones and royalties if the drug eventually reaches the market.
What Medicus actually bought
The asset in question is PF-08046031, also known as CD228V, an early clinical-stage ADC that targets melanotransferrin, a protein called CD228 that shows up on the surface of melanoma cells and several other solid tumors, including lung, head-and-neck and esophageal cancers. Pfizer had run a phase 1 trial of the drug starting in May 2025 focused primarily on advanced melanoma, but discontinued it as part of a broader trimming of assets it picked up in the Seagen deal. There are currently no approved drugs targeting CD228, which is part of what makes the asset attractive to a smaller company looking to stake out new ground rather than compete head-on in a crowded target class.
The money and the mechanics
According to Medicus’s Form 8-K filing with the Securities and Exchange Commission, the company paid Pfizer $12 million upfront and owes another $15 million on September 2, 2027, the deal’s first anniversary. Pfizer separately kicked in $2 million to help fund Medicus’s early development work on the program. If the drug clears development and hits regulatory and sales milestones across multiple indications, Pfizer stands to collect more than $1 billion in total, plus tiered royalties on any eventual sales. Medicus keeps control of day-to-day development, manufacturing and commercialization decisions, but it has to share its development plans and budgets with Pfizer, and Pfizer holds an option to step back in and help fund the program once a pivotal trial gets underway.
A small company betting big on a Big Pharma reject
Medicus Pharma is publicly traded on Nasdaq under the ticker MDCX and lists its principal executive offices at 300 Conshohocken State Road in Conshohocken, putting it firmly in the Philadelphia suburbs. The company has been building a precision oncology pipeline alongside its more established programs in dermatology and urology, including SkinJect, a non-invasive microneedle treatment for basal cell skin cancer, and Teverelix, a GnRH antagonist for prostate cancer. CEO Raza Bokhari, who also serves as executive chairman, called the Pfizer partnership a defining milestone for the company and said it significantly expands its footprint in precision oncology.
Earlier this week, BioBuzz reported on Medicus’s broader strategic focus toward precision led- oncology, with CD228V now positioned as the company’s flagship program while SkinJect gets refocused on the rare Gorlin syndrome indication and Teverelix’s prostate cancer work shifts toward outside partnerships. Taken together, the two moves show a small biotech consolidating around fewer, sharper bets rather than spreading itself thin.
Part of a pattern for Pfizer’s post-Seagen cleanup
This isn’t the first asset Pfizer has cut loose since absorbing Seagen’s ADC portfolio in a deal that closed in December 2023. Pfizer has steadily pared down its inherited pipeline, and the CD228V deal comes not long after another former Seagen program, the first of the acquired assets to reach a pivotal readout, failed a phase 3 trial in non-small cell lung cancer. For Pfizer, offloading early or underperforming assets to smaller companies willing to take on the development risk is a familiar way to recoup some value without continuing to fund programs that no longer fit its priorities. For Medicus, it’s a chance to get into precision oncology with a molecule that already has real clinical data behind it, even if that data didn’t convince Pfizer to keep going.
